Biotech giant Gilead lays off 104 from Bay Area headquarters, including execs
Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
FierceBiotech1d
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
BioSpace23h
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...
Gilead: Q3 Earnings Snapshot
FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Wednesday reported third-quarter net income of $1.25 billion. On a per-share basis, the Foster City, ...
Gilead’s third-quarter earnings beat by a wide margin, and biotech raises guidance
Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...
COVID drugmaker to close Seattle office, lay off 72 workers
The company behind the COVID-19 treatment drug remdesivir and the HIV antiretroviral medication Biktarvy is closing its ...
Times Union9d
Gilead: Q3 Earnings Snapshot
FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Wednesday reported third-quarter net income of $1.25 billion. On a per-share basis, the Foster City ...
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
New outcomes from two datasets derived from the Bictegravir Single Tablet Regimen (BICSTaR) study are consistent with the results observed from multiple Phase 3 clinical trials, which demonstrated the ...